Metabolomic Signatures for Predicting, Diagnosing, and Prognosing Various Diseases Including Cancer
AssigneeMetabolomycs, Inc.
InventorsRobert Nagourney, Ismael Silva, Paulo D'Amora
Life of this patent
Estimating the term…
Abstract
A system and method for using new biomarkers to assess individual diseases is provided. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and treat various diseases, including, but not limited to, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and acute graft-versus-host disease.
Claims20
A method for assessing a human patient for ovarian cancer, comprising:
- using a technology selected from chromatography, spectroscopy, and spectrometry to quantify a plurality of metabolites included in a blood sample obtained from said human patient, including at least Tiglylcarnitine and Glutaconylcarnitine;
- normalizing data values obtained in the quantification of at least said Tiglylcarnitine and said Glutaconylcarnitine, as quantified using said technology;
- comparing at least a result of an equation comprising at least a first ratio of said Tiglylcarnitine to said Glutaconylcarnitine, as normalized, to at least one predetermined value to both diagnose said human patient for said ovarian cancer and determine a prognosis for said human patient;
- wherein said diagnosis includes whether said human patient has ovarian cancer and said prognosis includes a risk factor associated with said ovarian cancer, said risk factor being a score on a linear scale that indicates at least one of a survival rate for said human patient and a response to treatment for ovarian cancer.
A system for assessing a human patient for ovarian cancer, comprising:
- a computing system comprising at least one memory device for storing machine readable instructions adapted to perform the steps of:
- receive a plurality of quantified metabolites from a sample provided by said human patient, including at least Tiglylcarnitine and Glutaconylcarnitine;
- normalize said plurality of quantified metabolites;
- compare at least a result of an equation comprising at least a first ratio of said Tiglylcarnitine to said Glutaconylcarnitine, as normalized, to at least one predetermined value to determine at least one level of similarity therebetween;
- and
- use said at least one level of similarity to determine a diagnosis and a prognosis for said human patient regarding said ovarian cancer;
- wherein said diagnosis includes at least whether said human patient has ovarian cancer and said prognosis includes at least a risk factor associated with said ovarian cancer, said risk factor being a score on a linear scale that indicates at least one of a survival rate for said human patient and a response to treatment for ovarian cancer.
Dependencies are inferred from the claim text.